Bruker Daltonics

Crown Bioscience offers next generation ion mobility-mass spectrometry (IM-MS)-based-proteomics services to global clients.

This will allow clients to assess the biological function of proteins for understanding signaling mechanisms within cells as well as specific biomarkers to diseases, and systematically assess quantitative differences in protein profiles of distinct samples for biomedical and clinical research.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

Bile acids are well known for their roles in cholesterol homeostasis, lipid absorption and as metabolic signaling molecules. They are implicated in a variety of disease states and therefore serve as an exciting focus on research in novel biomarker discovery.

Increased demand has led to an overwhelming volume of LC-MS/MS data and a requirement for analytical software that can simplify its interpretation. This poster highlights a new, comprehensive software solution capable of eliminating the otherwise overwhelming efforts of manual data interpretation.

Bruker Corporation today announced that is has closed the acquisition of ZONTAL Inc., an innovative platform provider for the digital transformation of the analytical laboratory, and for integrated biopharma technical data solutions.

At the 71st Annual Society for Mass Spectrometry (ASMS) meeting, Technology Networks had the pleasure of speaking with Rohan Thakur, president of Life Sciences Mass Spectrometry at Bruker Daltonics. We discussed the new product launches from Bruker and focused specifically on the applications of the company’s newest mass spectrometer, the timsTOF Ultra, for immunopeptidomics.

Need a routine analytical technique that can provide protein expression profiling and targeted drug imaging? MALDI Imaging is used to determine the spatial distribution of molecules in a tissue section, for more complete multiomic information.

Introducing midia-PASEF®, a groundbreaking DIA scan mode utilizing overlapping quadrupole windows for comprehensive ion analysis.

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for mRNA vaccines and nucleic acid-based drugs. Hence, the analysis of their composition, stability, and biological interactions is essential in drug development and delivery.

PreOmics GmbH announces the launch of its new ENRICHiST™ kits, which enable biologically unbiased enrichment of lower abundant plasma and serum proteins onto non-functionalized paramagnetic particles.